Recombinant Human Probable palmitoyltransferase ZDHHC8 (ZDHHC8)

What is ZDHHC8 and what are its structural characteristics?

ZDHHC8 (Zinc finger DHHC-type containing 8) is a palmitoyltransferase enzyme that catalyzes the addition of palmitate to specific protein substrates through S-palmitoylation. It is encoded by the ZDHHC8 gene located on chromosome 22 with Entrez Gene ID 29801 . The protein has a molecular weight of approximately 30.36 kDa . ZDHHC8 contains a characteristic DHHC domain that is critical for its catalytic activity. This domain is a cysteine-rich region that coordinates zinc ions and contains the DHHC (Asp-His-His-Cys) amino acid motif that gives this enzyme family its name.

For experimental validation of ZDHHC8's catalytic activity, researchers typically generate transferase-dead mutants (referred to as ZDHHS8) by replacing the critical cysteine residue in the DHHC motif with serine . This mutation abolishes palmitoyltransferase activity while maintaining protein structure, serving as an excellent negative control in palmitoylation assays.

How should recombinant ZDHHC8 protein be stored and handled in experimental settings?

Recombinant ZDHHC8 requires specific storage conditions to maintain structural integrity and enzymatic activity. Commercial recombinant human ZDHHC8 protein should be stored at -80°C and researchers should avoid repeated freeze-thaw cycles to prevent protein degradation and loss of activity .

The recombinant protein is typically supplied in a buffer containing 50 mM Tris-HCl and 10 mM reduced glutathione at pH 8.0 . This formulation helps maintain protein stability and solubility. When working with ZDHHC8:

• Always use fresh aliquots for critical experiments

• Keep the protein on ice when thawed

• Use protein purity verification methods (such as SDS-PAGE) before experimental applications

• Consider including protease inhibitors when working with the enzyme for extended periods

What experimental approaches can be used to study ZDHHC8-mediated protein palmitoylation?

Several methodological approaches are available for investigating ZDHHC8-mediated palmitoylation:

Acyl-Biotin Exchange (ABE) Assay: This technique identifies palmitoylated proteins by replacing thioester-linked palmitate with biotin. In experimental settings, Gp130 palmitoylation has been detected using ABE, with specificity confirmed by absence of signal when hydroxylamine (a key reagent) is omitted or when cells are treated with the palmitoylation inhibitor 2-bromopalmitate (2BP) .

Co-expression Studies: To determine if a protein is a direct substrate of ZDHHC8, researchers co-express the candidate substrate with wild-type or catalytically inactive ZDHHC8 in cell lines such as HEK293T. Significantly increased palmitoylation of a protein by wild-type ZDHHC8 but not by the transferase-dead mutant (ZDHHS8) indicates direct palmitoylation by ZDHHC8 .

Gene Knockdown Approaches: ShRNA-mediated knockdown of ZDHHC8 in neurons or other cell types allows researchers to assess the impact on substrate palmitoylation and downstream functions. For instance, Zdhhc5/8 knockdown reduced Gp130 palmitoylation in DRG neurons .

Surface Expression Analysis: Since palmitoylation often affects protein trafficking, surface biotinylation assays can be used to quantify changes in plasma membrane localization of ZDHHC8 substrates following manipulation of ZDHHC8 expression or activity .

What are the known substrates of ZDHHC8 and how are they identified?

ZDHHC8 has been shown to palmitoylate several important proteins in various cellular contexts:

To identify novel ZDHHC8 substrates, researchers typically employ:

• Palmitoyl-proteomics: Mass spectrometry-based approaches to identify proteins with reduced palmitoylation following ZDHHC8 knockdown or knockout

• Candidate approach: Testing specific proteins based on phenotypic similarities with ZDHHC8-deficient models

• Proximity labeling: Using BioID or APEX2 fused to ZDHHC8 to identify proteins in close proximity that may be substrates

What is the role of ZDHHC8 in epilepsy and seizure susceptibility?

ZDHHC8 has emerged as a critical regulator of neuronal excitability and seizure susceptibility. Studies show increased ZDHHC8 expression in temporal lobe epilepsy (TLE) patients and chronic epileptic mouse models, establishing a strong correlation between ZDHHC8 levels and human epilepsy .

Experimental evidence from in vivo models:

• Knockdown of ZDHHC8 using recombinant adeno-associated virus (rAAV) significantly delayed seizure precipitation in kainic acid- and pilocarpine-induced epileptic mouse models

• ZDHHC8 knockdown reduced chronic spontaneous recurrent seizures (SRSs) and epileptiform-like discharges

• Conversely, ZDHHC8 overexpression accelerated seizure onset and increased seizure severity

Cellular mechanisms:
ZDHHC8 exerts its effects primarily through modulation of AMPA receptor-mediated excitatory glutamatergic neurotransmission. Electrophysiological studies in acute hippocampal slices revealed that ZDHHC8 significantly affects the inward rectification of AMPA currents . Mechanistically, ZDHHC8 facilitates GluA1 trafficking to the neuronal surface in the hippocampus, thereby enhancing excitatory synaptic transmission.

Methodological approaches for studying ZDHHC8 in epilepsy:

• Viral-mediated gene manipulation: Using rAAV to knockdown or overexpress ZDHHC8 in specific brain regions

• Electrophysiological recordings: Whole-cell patch-clamp recordings in acute brain slices to measure AMPA receptor-mediated currents

• In vitro seizure models: Magnesium-free models to induce neuronal hyperexcitability and assess the impact of ZDHHC8 manipulation

How does ZDHHC8 contribute to axonal growth and neuronal connectivity in development and disease?

ZDHHC8 plays a crucial role in axonal development, particularly in the context of 22q11.2 deletion syndrome, which is associated with cognitive deficits and schizophrenia risk .

Developmental effects:

• ZDHHC8-deficient mice exhibit deficits in axonal growth during embryogenesis

• Mutant neurons show impaired terminal arborization, which can be prevented by reintroduction of enzymatically active ZDHHC8

• ZDHHC8 deficiency reduces the proportion of neurons developing a single axon (62.1±1.8% in Zdhhc8-/- vs. 77.0±0.9% in wild-type neurons)

• Axon length is significantly reduced in ZDHHC8-deficient neurons (305.2±22.2 μm in Zdhhc8-/- vs. 421.4±17.1 μm in wild-type neurons)

Molecular mechanism:
ZDHHC8 mediates its effects on axonal growth via Cdc42-dependent modulation of Akt/Gsk3β signaling at the axon tip. Pharmacological reduction of Gsk3β activity during postnatal brain development can reverse the axonal growth deficits in ZDHHC8-deficient models .

Functional consequences:

• Impaired terminal arborization of pyramidal neurons due to ZDHHC8 deficiency leads to reduced strength of synaptic connections

• This results in altered functional connectivity and spatial working memory deficits

• These structural connectivity changes may represent predisposing factors for psychiatric symptoms associated with 22q11.2 deletion

Experimental approaches:

• Neuronal culture analysis: Dissociated cortical neurons cultured and analyzed for axon polarity using Tau-1 (axon marker) and MAP2 (dendritic marker) antibodies

• Genetic rescue experiments: Reintroduction of wild-type or mutant ZDHHC8 to assess rescue of axonal phenotypes

• Pharmacological intervention: Using Gsk3β inhibitors to assess rescue of axonal growth deficits

What is the relationship between ZDHHC8 expression and cancer outcomes?

ZDHHC8 exhibits complex associations with cancer prognosis that vary by cancer type, suggesting context-dependent functions in oncogenesis .

Cancer correlation data:

• High expression of ZDHHC8 correlates with shorter survival times in renal and cervical cancers

• Conversely, high ZDHHC8 expression correlates with longer survival rates in lung and pancreatic cancers

Functional evidence from model organisms:
Studies in Drosophila show that ZDHHC8 knockdown causes tissue overgrowth, suggesting a potential tumor suppressor role in some contexts . The mechanism appears to involve palmitoylation of key growth regulators such as Scribble and Ras64B.

Research methodologies:

• Survival correlation analysis: Mining cancer databases to correlate ZDHHC8 expression with patient outcomes across different cancer types

• Genetic manipulation in model organisms: Using knockdown or overexpression approaches to assess effects on tissue growth

• Substrate identification: Identifying cancer-relevant palmitoylation targets of ZDHHC8 that may explain its context-dependent effects

How do ZDHHC5 and ZDHHC8 cooperatively regulate Gp130 palmitoylation and surface expression?

ZDHHC5 and ZDHHC8 exhibit unique properties in regulating Gp130, a critical cytokine receptor signaling component, through palmitoylation .

Experimental findings:

• Both ZDHHC5 and ZDHHC8 can directly palmitoylate Gp130 when co-expressed in HEK293T cells

• Wild-type forms of both enzymes significantly increase Gp130 palmitoylation, while their transferase-dead mutants (ZDHHS5 and ZDHHS8) do not

• In DRG neurons, combined Zdhhc5/8 knockdown more effectively reduces Gp130 palmitoylation than single knockdowns

• ZDHHC8 knockdown more markedly reduces Gp130 surface localization than ZDHHC5 knockdown

Mechanistic insights:

• ZDHHC5 and ZDHHC8 are likely localized to the axonal plasma membrane, explaining their effect on Gp130 surface expression

• Combined Zdhhc5/8 knockdown only partially reduces Gp130 palmitoylation, suggesting other PATs may palmitoylate Gp130 at different cellular locations

• Different palmitoylation sites on Gp130 may be targeted by different PATs, with ZDHHC5/8 potentially palmitoylating sites more critical for surface expression and signaling

Methodological approaches:

• Acyl-Biotin Exchange (ABE): To measure Gp130 palmitoylation levels

• Surface biotinylation assays: To quantify surface expression of Gp130

• Combined genetic approaches: Using single and double knockdowns to assess cooperative functions

What considerations are important when using recombinant ZDHHC8 protein in functional studies?

When using recombinant ZDHHC8 for functional studies, several important considerations should be addressed:

Specific applications:
Recombinant ZDHHC8 protein has been validated for several applications:

• Western Blot

• ELISA

• Protein Array

• Immunoaffinity Purification

Purity considerations:
Commercial preparations typically have >80% purity as assessed by SDS-PAGE and Coomassie blue staining . For applications requiring higher purity, additional purification steps may be necessary.

Activity assessment:
To verify enzymatic activity of recombinant ZDHHC8:

• Perform in vitro palmitoylation assays using purified substrate proteins

• Include positive controls (known ZDHHC8 substrates like Gp130)

• Include negative controls (non-substrate proteins or reactions with catalytically inactive ZDHHC8)

• Verify palmitate incorporation using either radiolabeled palmitate or ABE methodology

What strategies can be employed to modulate ZDHHC8 activity for potential therapeutic applications?

Given ZDHHC8's involvement in neurological disorders and cancer, modulating its activity presents potential therapeutic opportunities:

Pharmacological inhibition:

• Broad-spectrum palmitoylation inhibitors like 2-bromopalmitate (2BP) inhibit ZDHHC8 activity but lack specificity

• Development of selective ZDHHC8 inhibitors would require high-throughput screening approaches and structural biology insights

Genetic modulation:

• Viral-mediated knockdown approaches using shRNA or CRISPR-Cas9 have shown efficacy in preclinical models

• For epilepsy applications, rAAV-mediated ZDHHC8 knockdown delayed seizure precipitation and decreased chronic spontaneous recurrent seizures in mouse models

Downstream pathway modulation:

• In neuronal development contexts, targeting downstream effectors like Gsk3β pharmacologically can reverse ZDHHC8 deficiency effects

• ZDHHC8 deficiency impacts are mediated in part via Cdc42-dependent modulation of Akt/Gsk3β signaling

Considerations for therapeutic development:

• Cell-type specificity: Ensure targeted delivery to appropriate cell types

• Timing of intervention: Consider developmental windows where intervention would be most effective

• Substrate specificity: Target specific ZDHHC8-substrate interactions rather than global ZDHHC8 activity

• Disease context: Account for potentially opposing roles in different disease contexts

How can researchers distinguish between direct and indirect effects of ZDHHC8 manipulation in experimental systems?

Distinguishing direct from indirect effects of ZDHHC8 manipulation requires careful experimental design:

Substrate validation approaches:

• In vitro palmitoylation assays: Demonstrate direct palmitoylation using purified components

• Catalytic mutant controls: Compare effects of wild-type ZDHHC8 with catalytically inactive ZDHHS8 mutant

• Site-directed mutagenesis of substrate: Mutate putative palmitoylation sites (typically cysteines) in the substrate protein and assess if this abolishes ZDHHC8-dependent effects

Controls for indirect effects:

• Assess global palmitoylation changes: Use techniques like click chemistry or ABE coupled with proteomics to determine if ZDHHC8 manipulation causes widespread palmitoylation changes

• Examine expression levels of other PATs: Rule out compensatory expression changes in other ZDHHC enzymes

• Time-course experiments: Distinguish immediate (likely direct) versus delayed (possibly indirect) effects of ZDHHC8 manipulation

Rescue strategies:
When ZDHHC8 knockdown affects multiple cellular processes, determine which are due to direct palmitoylation by performing substrate-specific rescue experiments, such as expressing palmitoylation-mimetic versions of key substrates.

What are the challenges in interpreting contradictory findings regarding ZDHHC8 function across different experimental systems?

Researchers face several challenges when interpreting seemingly contradictory findings about ZDHHC8:

Context-dependent functions:
ZDHHC8 shows opposing associations with survival across different cancer types , suggesting its function depends on cellular context. Similarly, its neuronal functions may vary by brain region, developmental stage, or disease state.

Technical considerations:

• Knockout versus knockdown: Complete knockout may trigger compensatory mechanisms not seen with partial knockdown

• Acute versus chronic manipulation: Transient versus stable loss of ZDHHC8 may produce different phenotypes

• In vitro versus in vivo systems: Cell culture findings may not translate to intact organisms

Substrate availability:
ZDHHC8 function depends on substrate availability, which varies across tissues and cell types. For example, Gp130 palmitoylation by ZDHHC8 may be more significant in neurons than in other cell types where Gp130 expression is lower or where other PATs predominate.

Methodological approaches to address contradictions:

• Side-by-side comparison of models: Direct comparison using identical methodologies

• Conditional/inducible systems: Use of temporal and spatial control of ZDHHC8 manipulation

• Multi-omics approaches: Integration of transcriptomics, proteomics, and palmitoyl-proteomics data to build comprehensive models of ZDHHC8 function